Access’ Thiarabine Demonstrates Efficacy In Rheumatoid Arthritis Trial

Access’ preclinical data has demonstrated that thiarabine shows efficacy in the prevention and treatment of rheumatoid arthritis (RA). In a well-established animal model for RA, a good restoration of joint structure was observed in the studies, said the company.

In the preclinical trial, Thiarabine demonstrated a highly significant, dose-dependent amelioration of arthritis. Thiarabine treatment resulted in inhibition of disease pathology, with reduction of both inflammatory and erosive disease parameters, as well as protection from loss of cartilage matrix proteins. When used as a preventative treatment, thiarabine blocked the development of joint disease at the 60mg/kg/day dose level, and exhibited a reduction in disease incidence and severity at 20mg/kg/day.

Jeffrey Davis, President and CEO of Access, said; “Our current development focus for thiarabine is for the treatment of hematological cancers. But, we believe these new RA data provide compelling evidence that Thiarabine should be developed for rheumatoid arthritis as well.”

Access is actively seeking co-development partners for all applications of Thiarabine.